Kura Oncology to Report Third Quarter 2020 Financial Results

Rhea-AI Summary

Kura Oncology (KURA) will release its third quarter 2020 financial results on November 5, 2020, before U.S. markets open. A conference call and webcast will follow at 8 a.m. ET to discuss the results and provide a corporate update. The company focuses on developing precision cancer treatments, with its lead candidate, tipifarnib, in a registration-directed trial for HRAS mutant head and neck cancer. Kura also has KO-539, a menin inhibitor in Phase 1/2A trials for acute myeloid leukemia.

Positive

• Tipifarnib in registration-directed trial for HRAS mutant head and neck cancer.
• KO-539 currently in Phase 1/2A trials for relapsed/refractory acute myeloid leukemia.

Negative

• None.

SAN DIEGO, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that it will report third quarter 2020 financial results before the open of U.S. financial markets on Thursday, November 5, 2020. Kura’s management will host a webcast and conference call at 8 a.m. ET / 5 a.m. PT that day to discuss the financial results and provide a corporate update.

The live call may be accessed by dialing (877) 516-3514 for domestic callers and (281) 973-6129 for international callers and entering the conference code: 7456326. A live webcast and archive of the call will be available online from the investor relations section of the company website at www.kuraoncology.com.
        
About Kura Oncology

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of two wholly owned small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura’s most advanced drug candidate is tipifarnib, a potent, selective and orally bioavailable farnesyl transferase inhibitor currently in a registration-directed trial (AIM-HN) in patients with recurrent or metastatic HRAS mutant head and neck squamous cell carcinoma. The Company’s pipeline is also highlighted by KO-539, a potent and selective menin inhibitor currently in a Phase 1/2A clinical trial (KOMET-001) in patients with relapsed/refractory acute myeloid leukemia. For additional information about Kura, please visit the Company’s website at www.kuraoncology.com.

Contacts

Company:
Pete De Spain
Vice President, Investor Relations &
Corporate Communications
(858) 500-8803
pete@kuraoncology.com 

Investors:
Robert H. Uhl
Managing Director
Westwicke ICR
(858) 356-5932
robert.uhl@westwicke.com 

Media:
Jason Spark
Managing Director
Canale Communications
(619) 849-6005
jason@canalecomm.com 

FAQ

What are Kura Oncology's upcoming financial results?

Kura Oncology will report its third quarter 2020 financial results on November 5, 2020.

What time is the Kura Oncology conference call?

The conference call will be held at 8 a.m. ET / 5 a.m. PT on November 5, 2020.

How can I access Kura Oncology's conference call?

You can access the call by dialing (877) 516-3514 for domestic callers or (281) 973-6129 for international callers, using conference code: 7456326.

What is Kura Oncology currently developing?

Kura is developing precision medicines for cancer, with its lead candidate, tipifarnib, in advanced trials.